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Chondroitin Sulfate Proteoglycans Are Associated with the Lesions
of Alzheimer's Disease
DAVID A. DEWITT,* JERRY SILVER,* DAVID R. CANNING,* AND GEORGE PERRy*'t
*Department of Neurosciences and tDivision of Neuropathology, Institute of Pathology
Case Western Reserve University, Cleveland, Ohio 44106-4901

Chondroitin sulfate proteoglycans (CSPG) are extracellular matrix proteins inhibitory to neurite outgrowth in vitro and correlated with decreased neurite
outgrowth after CNS injury. Previously, heparan sulfate proteoglycan and dermatan sulfate proteoglycan
have been shown to be associated with senile plaques
(SPs) and neurofibrillary tangles (NFTs) but CSPG was
not. In an immunocytochemical study, three monoclonal antibodies to different sulfation states of the chondroitin glycosaminoglycan were used to localize CSPG
in cases of Alzheimer's disease. Chondroitin 4-sulfate
was found in both SPs and NFTs. An antibody to unsulfated chondroitin strongly immunostained intracellular NFTs and the dystrophic neurites of SPs. Chondroitin 6-sulfate was found in NFTs and the area around
SPs. These results suggest that CSPG, in addition or as
an alternative to ~-amyloid protein, could be responsible for the regression of neurites around senile plaques
in Alzheimer's disease. © 1993 Academic Press, Inc.

INTRODUCTION

Alzheimer's disease is a severe mentally debilitating
disease characterized by two principle lesions, the neurofibrillary tangle (NFT) and the senile plaque (SP). Senile plaques consist of a core of amyloid {3-protein (A{3),
a 39- to 42-amino acid peptide (13) derived from a larger
amyloid precursor protein (APP) (8). Dystrophic neurites containing APP (9) and processes of reactive astrocytes extend radially toward the A{3 core. Whether
the neurites are growing into the SP or are dying and/or
moving away from the plaque has not been determined.
The status of neurites is compounded by in vitro studies
in which A{3 has been shown to have both trophic and
toxic effects on neurons (29).
Proteoglycans are highly anionic proteins with one or
mOre glycosaminoglycans attached to the protein core.
They are one of the principle components of the extracellular matrix. Enzymatic digestion of glycosaminoglycans leaves a distinct antigenic sugar stub specific for
each type of glycan.

APP has been shown to be involved in the growth
regulation of different cell types (12, 17). In cultured
neurons, APP has been shown to be associated with the
extracellular matrix (11) and to mediate cell-cell and
cell-surface adhesion (4). Recently, APP was shown to
be a chondroitin sulfate proteoglycan core protein (19).
While the presence of chondroitin 4-sulfate (C-4) was
determined associated with APP, neither chondroitin
6-sulfate (C-6) nor un sulfated chondroitin (C-O) was
found attached to APP.
Chondroitin sulfate proteoglycans (CSPGs), C-6 in
particular, can inhibit neurite outgrowth in vitro (23,
24). CSPG may serve as an inhibitory barrier during
development providing for axon guidance (5). In adult
animals, CSPGs and reactive astrocytes have been
correlated with decreased neurite outgrowth in response to injury to the central nervous system (14).
Glial cells make and secrete CSPGs (15, 19). Additionally, a subpopulation of neurons have CSPG lining their
perimeter (3). The exact function of this neuronal proteoglycan is unknown.
Previously, proteoglycans have been found in SPs
and NFTs. Heparan sulfate proteoglycan has been
found in both SPs (21, 22, 26) and NFTs (16, 18, 26).
Decorin, a dermatan sulfate proteoglycan, was reported
to line the periphery of SPs and was localized to paired
helical filaments within NFTs (20). However, CSPGs
have not previously been found in either lesion.
In this immunohistochemistry study, we demonstrate
the presence of three differentially sulfated CSPGs in
the lesions of Alzheimer's disease.
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MATERIALS AND METHODS

Sections from frontal cortex or hippocampus from six
cases of Alzheimer's disease confirmed by pathological
examination (ages 69-85; postmortem interval 2-7 h)
and two controls (ages 57 and 78; postmortem interval
15-18 h) were studied. Tissue was fixed in methacarn
(methanol:chloroform:acetic acid, 6:3:1) and embedded
in parafin. Immunostaining was done by the peroxidase
anti-peroxidase method with 3',3'-diaminobenzidine as
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the cosubstrate (25). To detect C-6 CSPG core protein,
the monoclonal antibody 3B3 was used (7). Methacarnfixed sections were incubated with chondroitinase ABC
(ICN) or with chondroitinase AC (Sigma) in Tris-acetate buffer (pH 8 and pH 7.6, respectively) for 2 h at
37°C or overnight at 20°C followed by overnight incubation at 4°C with antibody. Heparinase and heparitinase treatments were also used as controls. SPs were verified by Congo red or staining adjacent sections with
4G8, (10) a monoclonal antibody to AfJ. Antibodies to
C-O and C-4 (IB5 and 2B6, respectively) were used to
determine whether these forms of CSPG were also present. NFTs were identified by double immunostaining
with an antisera to T (27). Anti-T utilized biotin-avidinconjugated alkaline phosphatase with Fast Blue as the
substrate.
RESULTS
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The antibody to unsulfated chondroitin strongly
stained dystrophic neurites around SPs (Fig. ID) and
intracellular NFTs (Figs. lA and ID). The staining of
NFTs was distinct from other neurons in the same section and from controls. Consistent with a previous report (3) a subset of neurons stained for unsulfated
chondroitin as a wide band along the neural perimeter
(data not shown).
Chondroitin 4-sulfate was localized to the perimeter
of Congo red-positive SPs (Fig. IH), NFTs (Fig. IB),
and dystrophic neurites (Figs. IE and IF). In order to
verify that the 2B6 antibody was recognizing C-4 instead of dermatan sulfate, the sections were treated
with chondroitinase AC, which does not digest dermatan sulfate (28). There was no apparent difference in
staining between either chondroitinase enzyme treatment (Figs. IE and IF) which suggests that chondroitin
4-sulfate is in fact associated with both SPs and NFTs.
C-6 was localized with the 3B3 antibody. Intense
staining was found at the immediate periphery of AfJ
deposits in senile plaques (Fig. IG). In addition, more
diffuse staining occurred further out around the SPs.
Most of the C6 immunoreactivity around SPs appeared
as an extracellular deposit around the SP. SPs were
identified by Congo red (Fig. 11) and adjacent sections
stained with 4G8, an antibody which recognizes AfJ. C-6
CSPG was also localized to T-positive NFTs (Fig. lC).
C-4 and C-6 were predominately confined to the area
around the SP core-the same area as dystrophic neurites and astrocytic processes although diffuse, light
staining occurred throughout the neuropil. None of the
chondroitin antibodies stained the core. Essentially
every NFT immunostained for T was also stained for all
three CSPGs with the CSPG staining much stronger,
making identification of T sometimes difficult. Almost
without exception these NFTs were intraneuronal since
the cytoplasm surrounding nuclei was apparent, indicating that CSPG is associated primarily with intraneu-

ronal tangles. None of the antibodies to CSPG immunostained any structure without previously treating the
sections with chondroitinase to digest the sugars.
Treatment with heparinase or heparitinase did not result in staining by the antibodies either. Immunoblots of
A68, T, ubiquitin, P-component, and neurofilaments did
not show binding of chondroitin antibodies with or
without chondroitinase digestion.

DISCUSSION

In this study, we have demonstrated the presence of
three differentially sulfated CSPGs in the lesions of
Alzheimer's disease. Unsulfated chondroitin, chondroitin 4-sulfate, and chondroitin 6-sulfate were all found
associated with SPs, NFTs, and dystrophic neurites.
Prior reports indicated that dermatan sulfate was
present in senile plaques and NFTs (20) while chondroitin sulfate was not (21). The antibodies used in
these previous studies to identify chondroitin sulfate
were raised to the glycosaminoglycan chains of CSPG.
We also saw no immunoreactivity with antibodies
raised to the CSPG sugar residues (data not shown).
Here, antibodies which recognize the chondroitinase-digested stub have been shown to recognize both SPs and
NFTs. Perhaps the sugar residues are masked by another protein or proteoglycan which prevents antibody
binding but not enzyme activity, thus allowing for exposure of the digested epitope.
Enzymatic digestion with chondroitinase AC specifically demonstrates the presence of C-4 as opposed to
dermatan sulfate. Chondroitinase ABC digests both
chondroitin and dermatan sulfate sugars while chondroitinase AC only digests chondroitin. Since both enzymes yielded a similar staining pattern, the antibody is
recognizing chondroitin. Dermatan sulfate would not be
stained after chondroitinase AC treatment. These results suggest that C-4 is present in SPs and NFTs. The
3B3 antibody to C-6 can also bind to C-O albeit with a
much lower affinity (1). IB5, which specifically binds to
C-O sites, did not stain SPs as strongly as 3B3 or with
the same pattern, suggesting that the immunolocalization of 3B3 is specific for C-6, at least around SPs.
The presence of C-6 around SPs is significant because
this glycosaminoglycan is particularly associated with
decreased neurite outgrowth in vitro and in response to
injury within the central nervous system. Large
amounts of C-6 around SPs could deter neurites from
growing in toward the SPs and may actually be causing
or mediating neuritic dystrophy. Interestingly, the area
which contains C6 immunoreactivity around the SP
overlaps with the area known to show a decrease in
neuritic density (2). Abnormal CSPG accumulation
could disrupt cell adhesion or growth factor utilization.
It is unclear whether each antibody is recognizing a
different CSPG core protein or the same core protein
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FIG. 1. Neurofibrillary tangles were identified with antisera to r (purple). Sections were treated with chondroitinase ABC prior to
addition of antibody. Monoclonal antibodies indicate different sulfation states of chondroitin sulfate proteoglycan (brown). Unsulfated
chondroitin (A), chondroitin 4-sulfate (B), and chondroitin 6-sulfate (C) are present in intracellular neurofibrillary tangles (N, nucleus).
CSPG can be found in the periphery of senile plaques. Note the absence ofCSPG immunoreactivity in A,B core of the senile plaque (c, core in D
through I). Dystrophic neurites are immunostained for r (D through G, arrows). Unsulfated chondroitin primarily stained dystrophic neurites
(D) and neurofibrillary tangles (arrowheads). Chondroitin 4-sulfate CSPG occurred with both chondroitinase ABC (E) and chondroitinase AC
(F). Chondroitin 6-sulfate surrounds the A,B core (G). Senile plaques immunostained for CSPG were verified by Congo red (H and I). Congo red
birefringence of the A,B core is seen as a green and yellow cross under polarized light. Scale bars = 20 /Lm.

with differentially sulfated chondroitin. Additionally,
.the same proteins could have other glycosaminoglycans
n?t digested by chondroitinase. These questions are significant because there could be multiple sources in brain
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for the different CSPGs or different forms may occur at
various stages of neuronal degeneration.
We have found in additional studies that astrocytes
accumulate CSPGs in response to AfJ (6), therefore, glia
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may be the source for some of the CSPGs. However,
since primarily intraneuronal NFTs were also stained, a
potential source of CSPG could be neuronal. In the case
of NFTs, CSPG accumulation may occur concurrently
with NFT formation. In the vicinity of SPs, both neurons and glia could interact synergisticly and accumulate various proteoglycans to produce a terrain refractory to neural regeneration.
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